Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9HAW0
UPID:
BRF2_HUMAN
Alternative names:
B-related factor 2; hBRFU
Alternative UPACC:
Q9HAW0; B2RD62; B4DFZ6; D3DSW6; Q9H2Y3; Q9H3B3; Q9NUY6
Background:
The Transcription factor IIIB 50 kDa subunit, also known as B-related factor 2 or hBRFU, plays a pivotal role in RNA polymerase III transcription. It is an essential activator for genes with promoter elements upstream of initiation sites, influencing gene expression under both normal and oxidative stress conditions. Its ability to down-regulate target genes during oxidative stress and protect cells against apoptosis underscores its significance in cellular defense mechanisms.
Therapeutic significance:
Understanding the role of Transcription factor IIIB 50 kDa subunit could open doors to potential therapeutic strategies.